口服抗凝药转肠外抗凝:Xa因子抑制剂特异性抗Xa浓度指导的作用
本研究为单中心回顾性队列研究,纳入2016年5月至2021年5月住院期间从口服Xa因子抑制剂(阿哌沙班或利伐沙班)转为治疗性肠外抗凝的845例患者,比较抗Xa浓度指导组(388例)与标准治疗组(457例)的大出血风险。结果显示浓度指导组大出血发生率显著低于标准治疗组(2.2% vs 11.3%,p<0.001),血栓栓塞并发症无差异(1.8% vs 1.5%,p=0.72),校正后大出血风险降低80%(HR 0.20,95%CI 0.10-0.39,p<0.01)。
要点
- 抗Xa浓度指导口服转肠外抗凝可显著降低大出血风险(2.2% vs 11.3%)。
- 浓度指导组从末次口服至肠外抗凝启动时间更长(27.9h vs 15.1h),血栓栓塞无增加。
- 校正后大出血风险降低80%(HR 0.20,95%CI 0.10-0.39)。
核心结论
- 使用Xa因子抑制剂特异性抗Xa浓度指导口服转肠外抗凝可能有助于减少特定患者群体的大出血。
研究设计与样本
- 观察性、单中心、回顾性队列研究,2016年5月至2021年5月,纳入从口服阿哌沙班或利伐沙班转为治疗性肠外抗凝的住院患者845例(浓度指导组388例,非浓度指导组457例)。
主要发现
- 浓度指导组大出血发生率显著低于非浓度指导组(2.2% vs 11.3%,p<0.001)。
- 两组血栓栓塞并发症无差异(1.8% vs 1.5%,p=0.72)。
- 浓度指导组从末次口服Xa因子抑制剂至肠外抗凝启动时间显著更长(27.9 h vs 15.1 h,p<0.01)。
- 浓度指导组大出血风险较非浓度指导组降低80%(校正HR 0.20,95%CI 0.10-0.39,p<0.01)。
关键数值与推荐
- 大出血依据国际血栓与止血学会(ISTH)标准判定。
- 主要结局为大出血,采用Cox比例风险模型评估与重大出血事件相关的患者特征。
临床怎么用
- 在住院患者从口服Xa因子抑制剂转为肠外抗凝时,可考虑采用Xa因子抑制剂特异性抗Xa浓度指导转换时机,以平衡出血与血栓风险。
局限性
- 本研究为观察性、单中心、回顾性队列研究,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The increasing use of oral factor Xa inhibitors (FXaI) has led to a growing interest in the clinical utility of laboratory monitoring to enhance safety and effectiveness. Particularly, the use of FXaI-specific anti-Xa concentrations has gained traction and been advocated for several indications, but limited studies have explored the role of anti-Xa concentrations in guiding inpatient transitions from oral to parenteral anticoagulants. Therefore, additional data on such approaches are warranted to help balance bleeding and thrombotic risks in the higher acuity inpatient setting. This study sought to compare two strategies for oral-to-parenteral anticoagulant transitions: FXaI anti-Xa concentration-guided versus standard of care (i.e., per-package insert). STUDY DESIGN: This was an observational, single-center, retrospective cohort study conducted from May 2016 to May 2021. Hospitalized patients converted from an oral FXaI (apixaban or rivaroxaban) to therapeutic parenteral anticoagulation with or without FXaI anti-Xa concentration guidance were reviewed. The primary outcome of major bleeding, according to the International Society on Thrombosis and Hemostasis criteria, was compared between groups. Cox proportional hazard modeling was used to evaluate patient characteristics associated with major bleeding events. RESULTS: A total of 845 patients (388 in the concentration-guided group and 457 in the non-concentration-guided group) met the inclusion criteria. Major bleeding was significantly lower in the concentration-guided versus the non-concentration-guided group (2.2% vs. 11.3%; p < 0.001, respectively). There were no differences between the groups in thromboembolic complications (1.8% concentration guided vs. 1.5% non-concentration guided; p = 0.72) despite a significantly longer time from last oral FXaI dose to parenteral anticoagulant initiation in the concentration-guided group (27.9 h vs. 15.1 h; p < 0.01). The concentration-guided group had an 80% lower risk of major bleeding compared with the non-concentration-guided group (adjusted hazard ratio [HR] 0.20, 95% confidence interval [CI] 0.10-0.39; p < 0.01). CONCLUSIONS: This analysis suggests using FXaI anti-Xa concentrations to guide the transition from oral to parenteral anticoagulants may be beneficial in reducing major bleeds in select patient populations.
引用
- Dinunno CV, Lopez CN, Succar L, et al. Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations. Pharmacotherapy. 2022. PMID: 36054446. doi:10.1002/phar.2726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。